Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in…

read more

Fall Advocacy Update: USP 797, E/M Documentation and Payment

Revisions to USP Chapter 797 Open for Comment Since the United States Pharmacopeia (USP) released…

read more

Brief Update on the Final CY 2019 Physician Fee Schedule

On November 1, the Centers for Medicare and Medicaid Services released the final Physician Fee…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/2018: Research Grant Cycle
Learn more

04/01/2019: 2019 Fellow Exam Application Deadline
Learn more

06/01/2019: Research Grant Cycle

06/7/19: Membership Application Deadline to be eligible for AAOA Member rate for the 2019 Basic Course

07/31/19: Membership Application Deadline to be voted in at the 2019 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2019 Annual Meeting
Learn more

EDUCATION

Codes/Guidelines

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

IFAR

IFAR Impact Factor: 2.135

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 Interactive Allergy & Rhinology Course
February 8-10, 2019 | Dallas, TX
Learn More and Register

2019 Basic Course in Allergy & Immunology
June 27-29 | Minneapolis, MN
Save the Date

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Save the Date

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

OTC Allergy Medications

There seem to be more and more medications available for allergy treatment that  you can now purchase over the counter.
The FDA is allowing previously prescription only drugs to be made available directly to the consumer without a prescription — adding more to the over-the-counter options in the healthcare aisles.

Read More

News and Updates

From the AAOA President, Matthew Ryan, MD

...the AAOA continues to be the organization that Otolaryngologists look to for up-to-date education and information on the…

read more

FDA Approves First Generic Version of EpiPen

The Food and Drug Administration approves the first generic version of EpiPen and EpiPen Jr.…

read more

Social and Networking Events at the 2018 AAOA Annual Meeting

This year’s Annual Meeting assures to be not only educational, interactive, and practice-centered, but also…

read more

Menu
AAOA Logo

Practice Resources

Compounding Updates

vials of allergens

As we continue to monitor activity both at the FDA and USP in relation to physician compounding, we wanted to offer the latest update.

USP: To provide a unified approach to quality compounding, USP is aligning the timing and content of General Chapters <795>, <797>, and <800>. Chapter <797> Pharmaceutical Compounding – Sterile Preparations is the chapter relating to allergy immunotherapy. Below is the current proposed timeline and web links for use during the public comment periods. AAOA will continue to monitor the progress and alert you when the revised version of <797> is released for comment.

Schedule & Links for Compounding Standards

Click the links for access where the respective information will be posted (Active after 2/28/2018)

 

 

 

<795>*

Pharmaceutical Compounding‒ Nonsterile Preparations

<797>*

Pharmaceutical Compounding Sterile Preparations

Pre-Posted on the USP Website for Public Comment**

 

 March 30, 2018 July 28, 2018
Published in the Pharmacopeial Forum

 

 May 1, 2018 September 4, 2018
Open Microphone Session

Registration will open

 April 20, 2018

 

 March 15, 2018

 

September 5, 2018

 

 August 5, 2018

 

Public Comment Period will close

 

 July 31, 2018

 

November 30, 2018
Intended Publication DateUSP – NF

 

 June 1, 2019

 

June 1, 2019
Anticipated Official Date

 

 December 1, 2019 December 1, 2019

*   The current published versions of USP-NF General Chapters <795> and <797> are official until new chapters become official.

** This pre-posting allows extra time, beyond the typical 90 day period, for stakeholders to review and provide input.

FDA: This morning the FDA held a stakeholder teleconference regarding its final guidance on compounded drug products.  The links below provide the summaries. FDA recognizes that compounded drugs play an important healthcare role for certain patients for whom FDA-approved drugs are not available, as well as the increased risk associated with compounding. As such, this guidance is intended to help reduce that risk.

The final guidance documents that we will discuss are:

Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf

Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510153.pdf

For additional information please visit FDA’s website: https://www.fda.gov/drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/

FDA Approval Updates

The U.S. Food and Drug Administration (FDA) recently approved the following sublingual tablets for pollen-induced allergies:

Merck’s RAGWITEK(TM), a sublingual immunotherapy tablet for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for short ragweed pollen. The complete press release from Merck is available:RAGWITEK.

Greer’s ORALAIR(R), a sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for any of the five grass species contained in the product (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass). The complete press release from Greer is available:ORALAIR.

Merck’s GRASTEK(R), a sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for Timothy Grass or cross-reactive grass pollens. The complete press release from Merck is available:<a “href=”http://www.aaoallergy.org/wp-content/uploads/2017/05/GRASTEK-press-release.pdf”>GRASTEK.

A Member Benefit

Allergy and Rhinology Journal (IFAR)

The International Forum of Allergy & Rhinology (IFAR) is the official journal of the AAOA and the American Rhinologic Society (ARS). Published monthly by John Wiley & Sons, Inc., IFAR provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions.

News

New Articles from IFAR

Medical therapy for Chronic Rhino-sinusitis

The indications for surgical management of chronic rhinosinusitis (CRS) in patients with cystic fibrosis (CF) are poorly defined..
Read More

Safety of long-term Intranasal Budesonide

The aim of this study was to determine the impact of long-term topical budesonide treatment via the mucosal atomization device (MAD) on the hypothalamic-pituitary-adrenal axis (HPAA) and intraocular pressure (IOP).. Read More

President Mims Message

April 2017

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices. Read More